To make cell therapies accessible for a global patient population by controlling growth with Osilaris automated scalable bioreactor for cell therapy manufacturing.
PamDx offers a blood-based immunotherapy guidance test, the IOpener®. The company’s kinase-activity profiling technology and software algorithms support clinicians in their treatment decisions.
Immunomatics leverages advanced machine learning and HLA compatibility modeling to assess the risk of specific donor-recipient mismatches, helping clinicians make more precise decisions.